{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:33:51Z","timestamp":1787924031917,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005481","name":"NYU Grossman School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.urology.2026.05.018","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:55:55Z","timestamp":1780329355000},"page":"74-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer"],"prefix":"10.1016","volume":"214","author":[{"given":"Herbert","family":"Lepor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Fiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majlinda","family":"Tafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Pirraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Wysock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2026.05.018_bib1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2018.01.002","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part II: recommended approaches and details of specific care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.05.018_bib2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.05.018_bib3","unstructured":"National Collaborating Centre for CancerEarly-Stage Prostate Cancer. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/prostate-early-patient.pdf. pp. 55-56."},{"key":"10.1016\/j.urology.2026.05.018_bib4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2026.05.018_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.urology.2017.10.014","article-title":"The use of magnetic resonance imaging to predict oncological control among candidates for focal ablation of prostate cancer","volume":"112","author":"Kenigsberg","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.urology.2026.05.018_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.urology.2024.10.039","article-title":"Five-year oncologic outcomes following primary partial gland cryo-ablation prospective cohort study of men with intermediate-risk prostate cancer","volume":"196","author":"Lepor","year":"2025","journal-title":"Urology"},{"key":"10.1016\/j.urology.2026.05.018_bib7","first-page":"11128","article-title":"Early functional outcomes following partial gland cryo-ablation","volume":"29","author":"Thakker","year":"2022","journal-title":"Can J Urol"},{"key":"10.1016\/j.urology.2026.05.018_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.urology.2022.10.003","article-title":"Two year functional outcomes stratified according to baseline erectile function following partial gland cryo-ablation","volume":"171","author":"Wysock","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.urology.2026.05.018_bib9","doi-asserted-by":"crossref","first-page":"398.e1","DOI":"10.1016\/j.urolonc.2025.02.001","article-title":"Functional, oncological, regret and complications following partial gland cryo-ablation for low-risk prostate cancer associated with MPMRI targets","volume":"43","author":"Lepor","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2026.05.018_bib10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41391-020-0244-0","article-title":"Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone","volume":"24","author":"Wysock","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2026.05.018_bib11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/JU.0000000000003569","article-title":"Biopsy assessment of oncologic control 3 years following primary partial gland cryoablation: a prospective cohort study of men with intermediate-risk prostate cancer","volume":"210","author":"Wysock","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.05.018_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.05.018_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamaoncol.2017.1879","article-title":"Adverse pathologic findings for men electing immediate radical prostatectomy: defining a favorable intermediate-risk group","volume":"4","author":"Patel","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2026.05.018_bib14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2026.05.018_bib15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","article-title":"Long-term results of active surveillance in the g\u00f6teborg randomized, population-based prostate cancer screening trial","volume":"70","author":"Godtman","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.05.018_bib16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bju.14935","article-title":"Active surveillance in intermediate-risk prostate cancer","volume":"125","author":"Klotz","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2026.05.018_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/CCO.0000000000000827","article-title":"Active surveillance in favorable intermediate risk prostate cancer: outstanding questions and controversies","volume":"34","author":"Russell","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.urology.2026.05.018_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/bju.16772","article-title":"Routine prostate biopsies not needed after cryotherapy if surveillance MRI is normal","volume":"136","author":"Lepor","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2026.05.018_bib19","article-title":"The performance of MPMRI to identify clinically significant prostate cancer (csPCA) following primary partial gland cryo-ablation (PPGCA)","volume":"213","author":"Lepor","year":"2025","journal-title":"J Urol [Internet]"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526003432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526003432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:07:51Z","timestamp":1787922471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429526003432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"alternative-id":["S0090429526003432"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2026.05.018","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2026.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}